Andrew Vaino, PhD
Senior Research Analyst
Roth Capital Partners, LLC
949-720-7102
Ian Sanderson, MBA
Research Analyst
Cowen and Company, LLC
617-946-3922
Doug Loe, PhD
Versant Partners Inc.
416-363-5757 Ext. 101
Cosme Ordoñez, BSc, MD, PhD
GMP Securities
514-288-9279
Claude Camiré
Senior Analyst, Biotech
Paradigm Capital
416-360-1322
Phillipa Flint
Analyst
RBC Dominion Securities Inc.
416-842-7854
William Tanner, PhD
Managing Director, Biotechnology
Leerink Swann and Co.
212-277-6020
David Dean, MBA
Analyst, Institutional Equity Research, Health Sciences
Cormark Securities Inc.
416-943-6722
Catherine Bouchard, MSc, MBA
Healthcare Analyst, Institutional Equity Research
Laurentian Bank Securities
514-350-2938
Neil Maruoka, MBA
Analyst, Life Sciences
Canaccord Adams Inc.
416.869.3073
Please note that any opinions, estimates or forecasts regarding Transition's performance made by the analysts listed above are theirs alone and do not represent opinions, forecasts or predictions of Transition Therapeutics Inc. or its management. Transition Therapeutics does not by its reference above or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations.
Senior Research Analyst
Roth Capital Partners, LLC
949-720-7102
Ian Sanderson, MBA
Research Analyst
Cowen and Company, LLC
617-946-3922
Doug Loe, PhD
Versant Partners Inc.
416-363-5757 Ext. 101
Cosme Ordoñez, BSc, MD, PhD
GMP Securities
514-288-9279
Claude Camiré
Senior Analyst, Biotech
Paradigm Capital
416-360-1322
Phillipa Flint
Analyst
RBC Dominion Securities Inc.
416-842-7854
William Tanner, PhD
Managing Director, Biotechnology
Leerink Swann and Co.
212-277-6020
David Dean, MBA
Analyst, Institutional Equity Research, Health Sciences
Cormark Securities Inc.
416-943-6722
Catherine Bouchard, MSc, MBA
Healthcare Analyst, Institutional Equity Research
Laurentian Bank Securities
514-350-2938
Neil Maruoka, MBA
Analyst, Life Sciences
Canaccord Adams Inc.
416.869.3073
Please note that any opinions, estimates or forecasts regarding Transition's performance made by the analysts listed above are theirs alone and do not represent opinions, forecasts or predictions of Transition Therapeutics Inc. or its management. Transition Therapeutics does not by its reference above or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations.
